Health Canada Approves Merck's Keytruda In Combination With Enfortumab Vedotin For Adult Patients With Unresectable Locally Advanced Or Metastatic Urothelial Cancer With No Prior Systemic Therapy
Portfolio Pulse from Benzinga Newsdesk
Health Canada has approved Merck's Keytruda in combination with Enfortumab Vedotin for treating adult patients with unresectable locally advanced or metastatic urothelial cancer who have not received prior systemic therapy.
August 22, 2024 | 11:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Health Canada's approval of Merck's Keytruda in combination with Enfortumab Vedotin for advanced urothelial cancer could boost Merck's oncology portfolio and potentially increase sales.
The approval by Health Canada expands the use of Keytruda, a key product in Merck's oncology portfolio, potentially leading to increased sales and market share in the cancer treatment sector.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90